Aquestive Historical Income Statement

AQST Stock

USD 5.09 0.07 1.36%

Historical analysis of Aquestive Therapeutics income statement accounts such as Selling General Administrative of 43.5 M, Total Revenue of 48.2 M or Gross Profit of 31.9 M can show how well Aquestive Therapeutics performed in making a profits. Evaluating Aquestive Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aquestive Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aquestive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aquestive Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

About Aquestive Income Statement Analysis

Aquestive Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aquestive Therapeutics shareholders. The income statement also shows Aquestive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Aquestive Therapeutics Income Statement Chart

At this time, Aquestive Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 92.3 M in 2024, whereas Net Loss is likely to drop (8.3 M) in 2024.

Selling General Administrative Total Revenue Net Income From Continuing Ops Ebit Cost Of Revenue Non Operating Income Net Other

Total Revenue

Total revenue comprises all receipts Aquestive Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Cost Of Revenue

Cost of Revenue is found on Aquestive Therapeutics income statement and represents the costs associated with goods and services Aquestive Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Aquestive Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aquestive Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.At this time, Aquestive Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 92.3 M in 2024, whereas Net Loss is likely to drop (8.3 M) in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	35.8M	28.3M	29.8M	31.9M
Total Revenue	50.8M	47.7M	50.6M	48.2M

Gross Profit Total Revenue

Aquestive Therapeutics income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Income	Net Interest Income	Depreciation And Amortization	Other Operating Expenses	Ebitda	Reconciled Depreciation	Non Operating Income Net Other
Interest Expense		0.64	0.34	0.34	-0.56	-0.71	-0.62	0.48	0.3	0.64	-0.71	-0.8	-0.77	0.7	-0.25	-0.53	-0.3	0.52	-0.65	-0.36	-0.48
Selling General Administrative	0.64		0.4	0.35	-0.94	-0.89	-0.89	0.67	0.46	0.99	-0.89	-0.49	-0.86	0.03	-0.38	-0.26	-0.58	0.97	-0.92	-0.46	-0.2
Total Revenue	0.34	0.4		0.98	-0.12	-0.19	-0.12	0.9	0.91	0.52	-0.19	-0.07	-0.16	0.12	0.2	-0.03	-0.1	0.3	-0.19	-0.07	-0.01
Gross Profit	0.34	0.35	0.98		-0.05	-0.16	-0.09	0.89	0.81	0.47	-0.16	-0.11	-0.14	0.18	0.15	-0.1	0.06	0.25	-0.15	0.08	0.09
Operating Income	-0.56	-0.94	-0.12	-0.05		0.93	0.96	-0.44	-0.24	-0.89	0.93	0.54	0.9	-0.03	0.55	0.35	0.61	-0.92	0.96	0.45	0.16
Net Income From Continuing Ops	-0.71	-0.89	-0.19	-0.16	0.93		0.99	-0.49	-0.22	-0.86	1.0	0.79	0.99	-0.32	0.71	0.63	0.42	-0.82	0.99	0.25	0.14
Ebit	-0.62	-0.89	-0.12	-0.09	0.96	0.99		-0.44	-0.17	-0.85	0.99	0.73	0.97	-0.21	0.74	0.59	0.42	-0.83	1.0	0.24	0.09
Research Development	0.48	0.67	0.9	0.89	-0.44	-0.49	-0.44		0.81	0.77	-0.49	-0.26	-0.45	0.18	-0.07	-0.21	-0.21	0.59	-0.5	-0.08	0.08
Cost Of Revenue	0.3	0.46	0.91	0.81	-0.24	-0.22	-0.17	0.81		0.56	-0.22	0.02	-0.18	-0.02	0.27	0.14	-0.43	0.38	-0.25	-0.38	-0.23
Total Operating Expenses	0.64	0.99	0.52	0.47	-0.89	-0.86	-0.85	0.77	0.56		-0.86	-0.47	-0.82	0.06	-0.34	-0.27	-0.54	0.95	-0.89	-0.41	-0.15
Income Before Tax	-0.71	-0.89	-0.19	-0.16	0.93	1.0	0.99	-0.49	-0.22	-0.86		0.79	0.99	-0.32	0.71	0.63	0.42	-0.82	0.99	0.25	0.13
Total Other Income Expense Net	-0.8	-0.49	-0.07	-0.11	0.54	0.79	0.73	-0.26	0.02	-0.47	0.79		0.85	-0.77	0.71	0.89	0.07	-0.36	0.72	-0.06	0.17
Net Income	-0.77	-0.86	-0.16	-0.14	0.9	0.99	0.97	-0.45	-0.18	-0.82	0.99	0.85		-0.41	0.7	0.67	0.41	-0.77	0.97	0.25	0.17
Income Tax Expense	0.7	0.03	0.12	0.18	-0.03	-0.32	-0.21	0.18	-0.02	0.06	-0.32	-0.77	-0.41		-0.3	-0.71	0.13	-0.12	-0.22	0.2	-0.11
Interest Income	-0.25	-0.38	0.2	0.15	0.55	0.71	0.74	-0.07	0.27	-0.34	0.71	0.71	0.7	-0.3		0.86	-0.14	-0.32	0.68	-0.36	-0.28
Net Interest Income	-0.53	-0.26	-0.03	-0.1	0.35	0.63	0.59	-0.21	0.14	-0.27	0.63	0.89	0.67	-0.71	0.86		-0.29	-0.14	0.56	-0.43	-0.15
Depreciation And Amortization	-0.3	-0.58	-0.1	0.06	0.61	0.42	0.42	-0.21	-0.43	-0.54	0.42	0.07	0.41	0.13	-0.14	-0.29		-0.61	0.47	0.83	0.49
Other Operating Expenses	0.52	0.97	0.3	0.25	-0.92	-0.82	-0.83	0.59	0.38	0.95	-0.82	-0.36	-0.77	-0.12	-0.32	-0.14	-0.61		-0.86	-0.48	-0.21
Ebitda	-0.65	-0.92	-0.19	-0.15	0.96	0.99	1.0	-0.5	-0.25	-0.89	0.99	0.72	0.97	-0.22	0.68	0.56	0.47	-0.86		0.29	0.12
Reconciled Depreciation	-0.36	-0.46	-0.07	0.08	0.45	0.25	0.24	-0.08	-0.38	-0.41	0.25	-0.06	0.25	0.2	-0.36	-0.43	0.83	-0.48	0.29		0.74
Non Operating Income Net Other	-0.48	-0.2	-0.01	0.09	0.16	0.14	0.09	0.08	-0.23	-0.15	0.13	0.17	0.17	-0.11	-0.28	-0.15	0.49	-0.21	0.12	0.74

Click cells to compare fundamentals

Aquestive Therapeutics Account Relationship Matchups

Aquestive Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	9.3M	13.0M	22.5M	12.4M	7.5M	9.5M
Selling General Administrative	64.3M	55.9M	53.5M	52.9M	31.8M	43.5M
Total Revenue	52.6M	45.8M	50.8M	47.7M	50.6M	48.2M
Gross Profit	32.2M	32.9M	35.8M	28.3M	29.8M	31.9M
Operating Income	(52.7M)	(42.9M)	(34.7M)	(42.1M)	(15.1M)	(15.9M)
Net Income From Continuing Ops	(66.2M)	(55.8M)	(70.5M)	(54.4M)	(7.9M)	(8.3M)
Ebit	(52.7M)	(42.8M)	(48.1M)	(42.0M)	(163K)	(171.2K)
Research Development	20.6M	19.9M	17.0M	17.5M	13.1M	16.7M
Cost Of Revenue	20.4M	13.0M	15.0M	19.4M	20.8M	16.3M
Total Operating Expenses	84.9M	75.8M	70.5M	70.4M	44.9M	60.5M
Income Before Tax	(66.2M)	(55.8M)	(70.5M)	(54.4M)	(7.6M)	(8.0M)
Total Other Income Expense Net	(13.6M)	(12.9M)	(35.9M)	(12.3M)	7.5M	7.9M
Net Income Applicable To Common Shares	(66.2M)	(55.8M)	(70.5M)	(54.4M)	(49.0M)	(51.4M)
Net Income	(72.7M)	(65.4M)	(90.0M)	(60.2M)	(7.9M)	(8.3M)
Income Tax Expense	6.4M	9.6M	19.5M	5.8M	245K	232.8K
Interest Income	636K	132K	423K	99K	16.3M	17.1M
Net Interest Income	(8.7M)	(12.9M)	(22.0M)	(12.3M)	8.9M	9.3M
Depreciation And Amortization	636K	3.6M	3.0M	2.4M	1.3M	2.2M
Other Operating Expenses	105.3M	88.7M	85.5M	89.7M	65.7M	92.3M
Ebitda	(52.0M)	(39.2M)	(45.1M)	(39.6M)	1.2M	1.2M
Reconciled Depreciation	2.9M	3.4M	3.0M	2.4M	1.3M	2.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aquestive Historical Income Statement

About Aquestive Income Statement Analysis

Aquestive Therapeutics Income Statement Chart

Total Revenue

Cost Of Revenue

Aquestive Therapeutics income statement Correlations

Aquestive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aquestive Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aquestive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 0.99	Selling General Administrative
Ebit	+ 0.99	Net Income From Continuing Ops
Net Income	+ 0.99	Net Income From Continuing Ops
Ebitda	+ 0.99	Net Income From Continuing Ops

Operating Income	- 0.94	Selling General Administrative
Other Operating Expenses	- 0.92	Operating Income
Ebitda	- 0.92	Selling General Administrative
Ebitda	- 0.89	Total Operating Expenses
Total Operating Expenses	- 0.89	Operating Income
Income Before Tax	- 0.89	Selling General Administrative